Process to allow choice of drug 'at the discretion of the clinician and patient'

The official statement from February's stakeholder meeting on the PBS-listing of the PDL1 inhibitor immunotherapies for lung cancer has confirmed that the outcome could see some of them funded outside their TGA approved indication. …